Dreaded “portfolio prioritisation” at BMS sees end to ADC deal with Eisai
ADCPhase 2Phase 1
Ongoing “portfolio prioritisation” efforts at Bristol Myers Squibb have scuppered a deal with Eisai to develop the Japanese pharm’s antibody-drug conjugate farletuzumab ecteribulin. Eisai said Monday that it now owns all rights to the folate receptor alpha (FRα)-targeting therapy and will conduct development alone.
Bristol Myers Squibb paid $650 million upfront back in 2021 to co-develop farletuzumab ecteribulin, then known as MORAb-202, as part of an alliance potentially worth over $3 billion. The ADC combines Eisai's humanised IgG1 monoclonal antibody farletuzumab, which binds to FRα, with its anticancer agent Halaven (eribulin), using an enzyme cleavable linker.
Farletuzumab ecteribulin is currently being evaluated in Phase II studies for non-small-cell lung, ovarian, peritoneal and fallopian tube cancers, as well as a Phase I/II trial for solid tumours. Eisai said Monday that it plans to “accelerate” the development of the agent as a high priority.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.